OncBioMune Pharmaceuticals, Inc. (OBMP: OTCQB) | OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer

Source: OTC Markets

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>